Dck-KO 基因敲除小鼠

1. Jiang, Tian-Yi, Cui, Xiao-Wen, Zeng, Tian-Mei, Dong, Li-Wei, Wang, Hong-Yang. 2023. PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK. In Science translational medicine, 15, eadd7464. doi:10.1126/scitranslmed.add7464. https://pubmed.ncbi.nlm.nih.gov/37437018/

2. Xiong, Junjie, Altaf, Kiran, Ke, Nengwen, He, Du, Liu, Xubao. . dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study. In Medicine, 95, e2936. doi:10.1097/MD.0000000000002936. https://pubmed.ncbi.nlm.nih.gov/26962792/

3. Song, Danjun, Wang, Yining, Zhu, Kai, Fan, Jia, Wang, Xiaoying. 2020. DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. In World journal of surgical oncology, 18, 176. doi:10.1186/s12957-020-01953-1. https://pubmed.ncbi.nlm.nih.gov/32690026/

4. Kulsoom, Bibi, Shamsi, Tahir Sultan, Afsar, Nasir Ali. 2018. Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin. In Cancer management and research, 10, 5573-5589. doi:10.2147/CMAR.S181299. https://pubmed.ncbi.nlm.nih.gov/30519105/